XPH: State Street SPDR S&P Pharmaceuticals ETF
Performance
Watchlist
Select an item
Summary
XPH at a glance
XPH returned +40.15% over the past year and +6.70% a year over five years. Its worst drop in that year was -16.45%, smaller than 35% of ETFs on Redstone, and its Sharpe ratio of 1.35 beats 91% of ETFs on Redstone. It yields 0.41%.
Current Drawdown
-8.98%
Rolling Volatility
32.52%
Dividends
XPH dividends
Yield
0.41%
Paid, past year
$0.27
Pays
Quarterly
Growth a year
-11.5%
Per share, by year
Yearly return over 5 years
XPH paid $0.27 a share over the past year, every quarter. Its yearly rate fell from $0.67 in 2022 to $0.46 in 2025, 11.5% a year. With dividends reinvested it returned +6.70% a year over five years, against +5.39% on price alone.
›All 20 payments since Dec 20, 2021
- Sep 21, 2026$0.0416
- Jun 22, 2026$0.059
- Mar 23, 2026$0.061
- Dec 22, 2025$0.113
- Sep 22, 2025$0.1026
- Jun 23, 2025$0.0959
- Mar 24, 2025$0.1533
- Dec 23, 2024$0.1548
- Sep 23, 2024$0.1947
- Jun 24, 2024$0.1557
- Mar 18, 2024$0.173
- Dec 18, 2023$0.1744
- Sep 18, 2023$0.1201
- Jun 20, 2023$0.1235
- Mar 20, 2023$0.1154
- Dec 19, 2022$0.194
- Sep 19, 2022$0.132
- Jun 21, 2022$0.1645
- Mar 21, 2022$0.1811
- Dec 20, 2021$0.1938
Metrics
Risk Indicators
Profile
About XPH
The State Street SPDR S&P Pharmaceuticals ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index, the Fund employs a sampling strategy, which means that the Fund is not required to purchase all of the securities represented in the Index.
From its prospectus, filed Oct 30, 2026- Category
- Health Care
- Expense ratio
- 0.35%
- Fund size
- $468M
- Inception
- Jun 2006
Comparisons